Profile image
Story Views

Last Hour:
Last 24 Hours:

$AZRX News – AzurRx CEO Provides Shareholders With a “State of the Union” Communication

Thursday, December 1, 2016 8:04
% of readers think this story is Fact. Add your two cents. News Alert: BROOKLYN, N.Y., – ( News Alert) – AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, announced today the release of a Company overview as presented by AzurRx’s President & CEO, Thijs Spoor.

Mr. Spoor began the communication by stating, “This Company overview serves to provide shareholders with a perspective on AzurRx, its evolution and future potential. Let me begin with the fundamentals. We have a clear, focused plan for value creation, building our pipeline assets with a short-term, lower-risk development pathway, an experienced management team and first-class advisors.

We believe that our focus on non-systemic therapies represents a new frontier for developing therapies. Our pipeline, led by MS1819 and followed by AZX1101, is moving ahead and we have further strengthened and we continue to expand our global patent portfolio. Non-absorbable drugs are a unique subset of orally administered agents that exert their therapeutic effects locally in the GI tract. In contrast to traditional drugs, which are designed to be rapidly absorbed, achieve therapeutic plasma levels, and then be eliminated by multiple pathways, non-absorbable drugs are designed to only act locally in the gut. It is our belief that if drugs are not absorbed into the bloodstream, then it is very difficult for them to reach the liver, heart, brain or other organs, and thus we believe that the chance of having serious side effects is decreased. Read this and more news for AZRX at

MS1819 – We continue to make progress with our lead agent MS1819-SD, a yeast derived recombinant lipase, for the treatment of exocrine pancreatic insufficiency (“EPI”) related to chronic pancreatitis (“CP”) and cystic fibrosis. We previously announced the initiation of the Phase II trial of MS1819 in EPI due to CP. We anticipate active participation from the sites in Australia and New Zealand in this un-blinded dose escalation trial, with initial results anticipated in the first half of 2017. With a potentially superior efficacy profile, we expect MS1819 to provide a true clinical…


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.